ЭFFICACY AND TOLERABILITY OF LENVATINIB IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
Keywords:
To analyze the aggregated clinical, lenvatinib, radioiodine-refractory thyroid cancer, clinical practiceAbstract
The introduction of tyrosine kinase inhibitors into clinical practice has significantly improved treatment outcomes for patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for this category of patients
Downloads
Published
2024-06-10
How to Cite
ЭFFICACY AND TOLERABILITY OF LENVATINIB IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER. (2024). Western European Journal of Medicine and Medical Science, 2(6), 11-20. https://westerneuropeanstudies.com/index.php/3/article/view/1131
Issue
Section
Articles
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
ЭFFICACY AND TOLERABILITY OF LENVATINIB IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER. (2024). Western European Journal of Medicine and Medical Science, 2(6), 11-20. https://westerneuropeanstudies.com/index.php/3/article/view/1131